Killer not happy with show
'Fearless' dog survives fall
Green Party deputy jailed
Facial recognition at border?
PM ups attacks on Poilievre
CRA will get the money: PM
Ukraine uses new missiles
Biden signs war aid measure
New US rules for airlines 
BoC officials split on rate cut
Big loss for Boeing 
Metro sales edged higher
Vees dominating Vipers
Warriors snakebitten in loss
Iginla off to Europe
Coachella fined $28K
Those are her nipples
Kanye to launch porn studio
Business Apr 23 - 6,637 views
Valeant Pharmaceuticals said Monday it has grown the sales force at its Salix drug business by about 250 people over the past three months.
The company, based in Laval, Que., said the 40 per cent increase to its existing sales staff will help grow market share and build relationships with doctors that may prescribe its gastrointestinal drugs.
One of the Salix drugs, Xifaxan, is for treating irritable bowel syndrome with diarrhea. Another Salix gastrointestinal drug, Relistor, is for treating opioid-induced constipation.
Valeant purchased Salix in April 2015 for US$11.1 billion. It wrote down Salix's value in November by US$1.05 billion in the third quarter.
In December, Valeant CEO Joseph Papa said the company would try to expand the sale of prescriptions for products like Xifaxan by launching a program directed at primary care physicians.
